IBI3026 / Innovent Biologics - LARVOL DELTA

This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=300 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial • Solid Tumor

Topic: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the breaks in immune response and strongly activating T and NK cells in the tumor microenvironment (PRNewswire) - "Innovent Biologics...announces that preclinical data...from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025....IBI3026 demonstrated potent immune activation (STAT4/IFN-γ signaling) in pre-treated human PBMCs and achieved complete tumor suppression in multiple models (EMT6, CT26, A375, BxPC-3). In cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) of IBI3026 is 150 mg/kg and the calculated therapeutic index is 63."

Preclinical • Solid Tumor

IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment (AACR 2025) - "In humanized A375 (melanoma) and BxPC-3 (pancreatic cancer) CDX models, IBI3026 showed much stronger tumor inhibitory effects than IBI308 (anti-PD-1 monoclonal antibody) and showed good safety profiles. These results demonstrate the good safety profile of IBI3026. In conclusion, IBI3026 is a first-in-class anti-PD-1/IL-12 immune agonist with high tumor inhibition potential and excellent safety profiles."

Biomarker • Immuno-oncology • Tumor microenvironment • Breast Cancer • Colorectal Cancer • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • IFNG • IL12A • STAT4

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting (PRNewswire) - "Innovent Biologics...announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025."

Preclinical • Acute Myelogenous Leukemia • T Acute Lymphoblastic Leukemia